Drugs giant GSK posts upbeat Q3

British drugmaker GlaxoSmithKline on Wednesday posted rising third-quarter earnings and revenues, buoyed by sales of HIV drugs and its asset swap deal with Swiss peer Novartis.

Net profit, or earnings after taxation, rallied 34 percent to £538 million ($825 million, 746 million euros) in the three months to September compared with the same period a year earlier, GSK said in a statement.